Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

UCB 34714

Known as: UCB-34714, UCB34714 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Brivaracetam

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Highly Cited
2011
Highly Cited
2011
Brivaracetam (UCB 34714)
Highly Cited
2010
Highly Cited
2010
Brivaracetam (ucb 34714) inhibits Na+ current in rat cortical neurons in culture
Highly Cited
2008
Highly Cited
2008
Anti‐convulsive and anti‐epileptic properties of brivaracetam (ucb 34714), a high‐affinity ligand for the synaptic vesicle protein, SV2A
Screening of 12 000 compounds for binding affinity to the synaptic vesicle protein 2A (SV2A), identified a high‐affinity… 
2008
2008
Brivaracetam: a new drug in development for epilepsy and neuropathic pain
Background: Epilepsy is a neurological disorder with a worldwide prevalence estimated to be 0.5 – 1.0% of the population. Many… 
Review
2007
Review
2007
Brivaracetam (UCB 34714).
  • P. von Rosenstiel
  • Neurotherapeutics : the journal of the American…
  • 2007
  • Corpus ID: 43350812
Brivaracetam (UCB 34714) is chemically related to levetiracetam (LEV, Keppra). It possesses a binding affinity for the synaptic… 
Review
2006
Review
2006
New antiepileptic drugs that are second generation to existing antiepileptic drugs
  • M. Bialer
  • Expert opinion on investigational drugs
  • 2006
  • Corpus ID: 21166138
In the last decade, 10 new antiepileptic drugs (AEDs) have been introduced that offer appreciable advantages in terms of their… 
Review
2005
Review
2005
Brivaracetam UCB.
Brivaracetam (UCB-34714), an orally active, high-affinity synaptic vesicle protein 2A ligand, is being developed by UCB for the… 
Review
2004
Review
2004
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII)
The Seventh Eilat Conference on New Antiepileptic Drugs (AEDs) (EILAT VII) took place in Villasimius, Sardinia, Italy from the… 
Highly Cited
2004
Highly Cited
2004
Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity.
(S)-alpha-ethyl-2-oxopyrrolidine acetamide 2 (levetiracetam, Keppra, UCB S.A.), a structural analogue of piracetam, has recently… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE